Lansoprazole in children: Pharmacokinetics and efficacy in reflux oesophagitis

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 9, 2001, Pages 1397-1402

  Faure, C ^a   Michaud, L ^b   Khan Shaghaghi, E ^a   Popon, M ^a   Laurence, M ^a   Mougenot, J F ^a   Hankard, R ^a   Navarro, J ^a   Jacqz Aigrain, E ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH PH; TREATMENT INDICATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ANTI-ULCER AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROESOPHAGEAL REFLUX; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; INFANT; MALE; METABOLIC CLEARANCE RATE; OMEPRAZOLE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0034840446     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01076.x     Document Type: Article

References (18)

1. Possible mechanism for the inhibition of gastric (H+.K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749
2. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
3. The effects of oral doses of lansoprazole and omeprazole on gastric pH
4. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers
5. Correlation of esophageal lengths in children with height: Application to the Tuttle test without prior esophageal manometry
6. Determination of lanzoprazole and five metabolites in plasma by high-performance liquid chromatography
7. Pharmacokinetics and absolute bioavailability of lansoprazole
8. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders
9. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori
10. Omeprazole
11. Pharmacokinetics of lansoprazole in adolescents with GERD
12. Adolescent patients with gastroesophageal reflux disease: Results from a randomized trial of lansoprazole
13. Pharmacokinetics/pharmacodynamics of lansoprazole in pediatric patients with symptomatic gastroesophageal reflux disease
14. Identification of the human P450 enzymes involved in lanzoprazole metabolism
15. Pharmacogenetics in paediatrics. Implications for practice
16. Pharmacokinetics of orally administered omeprazole in children: International Pediatric Omeprazole Pharmacokinetic group
17. Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements
18. Acid secretion and response to pentagastrin or omeprazole in human fetal stomach xenografts